Study of epidemiology, clinicopathological correlation, prognostic factors and management in squamous cell carcinoma of vulva

Authors

  • Chetana D. Parekh Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
  • Ruchi S. Arora Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
  • Shilpa M. Patel Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
  • Pabashi Poddar Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
  • Ava D. Desai Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India
  • Meeta M. Mankad Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20185428

Keywords:

HPV infection, Overall survival, Radical vulvectomy with groin dissection, Recurrence, Vulvar cancer

Abstract

Background: Carcinoma of the vulva is rare cancer, pruritus is the most common and long-lasting reported symptom. It is found to be associated with HPV and HIV infection. Currently, a more individualized and less radical treatment is suggested. In this study we evaluated epidemiology, clinicopathological prognostic factors, HPV distribution and risk factors for metastases to lymph nodes. We also reviewed multidisciplinary clinical management carried out at our institute.

Methods: It is a prospective study of 25 biopsy proven cases of Squamous Cell Carcinoma of Vulva, treated at our center from September 2014 to September 2016. We collected the data regarding the clinical presentation, histological details, treatment given, survival and complications. HPV 16 and 18 testing were done using PCR method. Median follow up of the patients are for 24 months.

Results: The mean age of patients was 54.6 years. Commonest presentation was perineal itching (36%). HPV 16/18 were positive in 25% of the patients. Radical vulvectomy with bilateral groin dissection was done in 14/25 (56%) patients. Among these 14 patients, 35.7 % (5/14) has lymph node metastases, disease free survival was 63.6% and overall survival was 81.1% for median follow up of 24 months. About one third of the patient presented with locally advanced disease.  Six (24%) patients received only chemo radiation as a treatment.

Conclusions: HPV and HIV infection increase the risk of vulvar cancer. Individualization of treatment is necessary. The use of preoperative chemoradiation in locally advanced disease might have promising results in future.

Author Biography

Chetana D. Parekh, Department of Gynaecologic Oncology, The Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India

 

 

References

Ibrahim Alkatout, Melanie Schubert, Nele Garbrecht, Marion Tina Weigel, Walter Jonat, Christoph Mundhenke. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Women’s Health 2015;7:305-13.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.

Carter J, Carlson J, Fowler J, Hartenbach E, Adcock L, Carson L, et al. Invasive vulvar tumors in young women: A disease of the immunosuppressed? Gynecol Oncol. 1993;51(3):307.

Ansink AC, Krul MR, De Weger RA, Kleyne JA, Pijpers H, Van Tinteren H, et al. Human papillomavirus, lichen sclerosus, and squamous cell carcinoma of the vulva: Detection and prognostic significance. Gynecol Oncol 1994;52(2):180.

Rakislova N, Saco A, Sierra A, Del Pino M, Ordi J. Role of Human Papillomavirus in Vulvar Cancer. Adv Anat Pathol. 2017;24(4):201-14

T. S. Mohan Rao, Sravani Sandhya Bellam, and P. Gurupuprasad. Vulvar invasive squamous cell carcinoma in a young patient with Human Immunodeficiency Virus-seropositivitivity. Indian J Sex Transm Dis AIDS. 2015;36(2):204-6

Siegler E, Segev Y, Mackuli L, Auslender R, Shiner M, Lavie O. Vulvar and Vaginal Cancer. Vulvar Intraepithelial Neoplasia and Vaginal Intraepithelial Neoplasia: Experience of a Referral Institute. ISR Med Assoc J. 2016;18(5):286-9.

Yetmen Ö, Eren MD, Ozdemir Z, Unal O, Mayadaglı A. The Prognostic Factors and Treatment Outcome of Squamous Cell Carcinoma of the Vulva: A Mono Institutional Study. JSM Clin Oncol Res. 2015;3(1): 1040.

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N et al Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study. JNCI J Natl Cancer Inst. 2015;107(3):426

Hampl M, Deckers-Figiel S, Hampl JA,etal. New aspects of vulvar cancer: Changes in localization and age of onset. Gynecol Oncol. 2008;109(3):340-5.

Lai J, Elleray R, Nordin A, Hirschowitz L, Rous B, Gildea C, Poole J. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG. 2014;121(6):728-38.

Hunter DJ. Carcinoma of the vulva: a review of 361 patients. Gynecol Oncol. 1975;3(2):117-23.

Philip J. DiSaia. Noninvasive vulvar lesions An illustrated guide to diagnosis and treatment Dystrophies, vulvodynia, and other noncancerous lesion. December, OBG Management 2006:18(12):62-79.

Vulvar nonneoplastic epithelial disorder. ACOG educational bulletin number 241, 1997. American College of obstetrician and Gynecologist, Washington, DC.

Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;12:(359):108-13.

Swarupa Mitra, Manoj Kumar Sharma, Inderjeet Kaur. Ruparna Khurana, Kanika Batra Modi, et al. Vulvar carcinoma: dilemma, debates, and decisions. Cancer Manag Res J. 2018;10:61-68.

Hoffman MS. Squamous-cell carcinoma of the vulva: locally advanced disease. Best Pract Res Clin Obstet Gynaecol. 2003;17(4):635-47.

Jeevarajan S, Duraipandian A, Kottayasamy Seenivasagam R, Shanmugam S, Ramamurthy R. Treatment Outcome of Carcinoma Vulva Ten-Year Experience from a Tertiary Cancer Centre in South India. Cancer Manag Res. 2018;10:61-8.

Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):529-33.

Sharma DN, Rath GK, Kumar S, Bhatla N, Julka PK, Sahai P. Treatment outcome of patients with carcinoma of vulva: Experience from a tertiary cancer center of India. J Cancer Res Therapeut. 2010;6(4):503-7.

Hacker NF, Berek JS, Juillard GJ, Lagasse LD. Preoperative radiation therapy for locally advanced vulvar cancer. Cancer. 1984;54(10):2056-61.

Woelber L, Eulenburg C, Choschzick M, Kruell A, Petersen C, Gieseking F, et al. Prognostic role of lymph node metastasis in vulval cancer and implication of adjuvant treatment. Int J Gynecol Cancer. 2012;22(3):503-8.

Downloads

Published

2018-12-26

Issue

Section

Original Research Articles